Translating safety, efficacy and compliance into economic value for controlled release dosage forms

Area of Science:

• Pharmacoeconomics
• Pharmaceutical Sciences
• Clinical Therapeutics

Background:

• Advanced controlled release (CR) dosage forms are emerging pharmaceutical products.
• Limited data exist on the economic value of CR dosage forms compared to conventional ones.
• Efficacy, safety, and compliance benefits of CR forms require economic assessment.

Purpose of the Study:

• To assess the cost-effectiveness of controlled release (CR) dosage forms.
• To compare economic value, including total treatment costs and therapeutic outcomes, of CR versus non-CR formulations.
• To examine three therapeutic areas: cardiovascular, pain management, and estrogen replacement.

Main Methods:

• Literature review assessing cost-effectiveness measures.
• Analysis of purchase costs, total treatment costs, and economic value of improved outcomes.
• Examination of CR dosage forms in cardiovascular therapy, pain management, and estrogen replacement.

Main Results:

• In cardiovascular therapy, CR formulations (e.g., sustained release verapamil, diltiazem, nifedipine, transdermal clonidine) showed improved compliance and reduced overall healthcare expenditures despite higher initial costs.
• CR metoprolol demonstrated effective beta-blockade without the adverse effects on well-being associated with conventional atenolol peaking plasma concentrations.
• Transdermal nitroglycerin improved quality of life and reduced adverse events and healthcare utilization compared to oral nitrates.

Conclusions:

• Controlled release dosage forms demonstrate significant cost-effectiveness, primarily driven by improved patient compliance and reduced non-drug healthcare costs.
• CR formulations offer economic advantages across various therapeutic areas, including cardiovascular disease and pain management.
• Optimized drug delivery via CR forms enhances therapeutic outcomes and patient well-being, translating to economic value.